Compare STRS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | IKT |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 220.5M |
| IPO Year | 1994 | 2020 |
| Metric | STRS | IKT |
|---|---|---|
| Price | $19.70 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 102.9K | ★ 1.0M |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 512.50 | 57.76 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $29,914,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.53 | $1.33 |
| 52 Week High | $32.93 | $2.53 |
| Indicator | STRS | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 16.48 | 54.63 |
| Support Level | $18.51 | $1.63 |
| Resistance Level | $20.57 | $2.31 |
| Average True Range (ATR) | 0.74 | 0.17 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 24.02 | 40.83 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.